DXRNasdaqFiscal year ends December 31
DAXOR CORP
Financials through Q4 FY2011, quarter ended Dec 31, 2011
$9.84−0.21 (-2.09%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- 2.54%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
10.1%
0M of 4M shares
Institutional holders
14
1 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
7 buys · 0 sales
Net bought $18.97K
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DXR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Thompson Siegel & Walmsley LLC | 241,767 | 5.76% | $2.49K | +9,647 | 0.04% |
| Vanguard Capital Management LLC | 48,831 | 1.16% | $495.64K | +551 | 0.00% |
| Aristides Capital LLC | 41,689 | 0.99% | $429.18K | −3 | 0.08% |
| Renaissance Technologies LLC | 29,421 | 0.70% | $302.88K | +1,410 | 0.00% |
| Susquehanna International Group, Llp | 27,131 | 0.65% | $275.38K | +13,411 | 0.00% |
| Nano Cap New Millennium Growth Fund L P | 12,500 | 0.30% | $128.69K | – | 0.10% |
| Crescent Grove Advisors, LLC | 12,423 | 0.30% | $127.89K | +1,700 | 0.01% |
| SBI Securities Co., Ltd. | 3,131 | 0.07% | $32.23K | +3 | 0.00% |
| Morgan Stanley | 3,087 | 0.07% | $31.78K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 1,037 | 0.02% | $10.53K | – | 0.00% |
| Osaic Holdings, Inc. | 500 | 0.01% | $5.15K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 305 | 0.01% | $3.14K | +196 | 0.00% |
| UBS Group AG | 172 | 0.00% | $1.77K | New | 0.00% |
| JPMorgan Chase & Co | 6 | 0.00% | $61 | +5 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 14 | 0M | 10.1% | 1 / 8 | 1 / 1 | 0M | 0M |
| Q1 2026 | 14 | 0M | 10.0% | 8 / 0 | 3 / 1 | 0M | 0M |
| Q4 2025 | 8 | 0M | 2.3% | 3 / 0 | 3 / 1 | 0M | 0M |
| Q3 2025 | 6 | 0M | 2.0% | 1 / 2 | 1 / 1 | 0M | 0M |
| Q2 2025 | 6 | 0M | 2.4% | 0 / 1 | 1 / 1 | 0M | 0M |
| Q1 2025 | 7 | 0M | 2.3% | 0 / 3 | 3 / 2 | 0M | 0M |
| Q4 2024 | 9 | 0M | 2.5% | 1 / 4 | 1 / 1 | 0M | 0M |
| Q3 2024 | 9 | 0M | 2.1% | 3 / 1 | 2 / 0 | 0M | 0M |
| Q2 2024 | 6 | 0M | 1.9% | 0 / 2 | 1 / 1 | 0M | 0M |
| Q1 2024 | 7 | 0M | 1.8% | 2 / 2 | 0 / 1 | 0M | 0M |
| Q4 2023 | 6 | 0M | 1.5% | 2 / 2 | 1 / 1 | 0M | 0M |
| Q3 2023 | 5 | 0M | 1.5% | 1 / 1 | 1 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DXR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 48,831 | 1.16% | $495.63K | 0.00% | Jun 30, 2026 |
| Gabelli Global Mini Mites Fund | 400 | 0.01% | $4.06K | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Richard Feldschuh | Chief Executive Officer, Director | 243,694 | 5.81% | Jun 25, 2026 |
| Jonathan Adam Feldschuh | Chief Scientific Officer, Director | 78,908 | 1.88% | Jun 25, 2026 |
| John Jefferies | Chief Medical Officer | 26,008 | 0.62% | Sep 1, 2026 |
| Robert J. Michel | Chief Financial Officer | 33,050 | 0.79% | Jun 25, 2026 |
| Caleb DesRosiers | Director | 3,157 | 0.08% | Jun 25, 2026 |
| Edward Feuer | Director | 1,000 | 0.02% | Jun 25, 2026 |
| Joy S. Goudie | Director | 300 | 0.01% | Jun 25, 2026 |
| Henry D. Cremisi | Director | – | – | Jun 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Jefferies Chief Medical Officer | Aug 28, 2026 | Award | +2,451 | – | – | 26,008 |
| Michael Richard Feldschuh Chief Executive Officer, Director | Jun 23, 2026 | Award | +30,000 | – | – | 243,694 |
| Jonathan Adam Feldschuh Chief Scientific Officer, Director | Jun 23, 2026 | Award | +25,000 | – | – | 78,908 |
| Robert J. Michel Chief Financial Officer | Jun 23, 2026 | Award | +12,000 | – | – | 33,050 |
| Michael Richard Feldschuh Chief Executive Officer, Director | Apr 8, 2026 | Buy | +1,000 | $9.07 | $9.07K | 213,694 |
| Robert J. Michel Chief Financial Officer | Mar 31, 2026 | Buy | +1,000 | $9.90 | $9.90K | 21,050 |
| John Jefferies Chief Medical Officer | Mar 20, 2026 | Buy | +3,656 | – | – | 21,272 |
| John Jefferies Chief Medical Officer | Mar 20, 2026 | Buy | +2,285 | – | – | 23,557 |
| Jonathan Adam Feldschuh Chief Scientific Officer, Director | Dec 9, 2025 | Buy | +18,000 | – | – | 53,908 |
| Robert J. Michel Chief Financial Officer | Dec 9, 2025 | Buy | +3,000 | – | – | 20,050 |
| John Jefferies Chief Medical Officer | Nov 12, 2025 | Buy | +2,344 | – | – | 17,616 |
| Michael Richard Feldschuh Chief Executive Officer, Director | Apr 4, 2025 | Buy | +2,063 | $7.89 | $16.28K | 212,694 |
| Robert J. Michel Chief Financial Officer | Mar 10, 2025 | Buy | +1,000 | $8.00 | $8.00K | 17,050 |
| Michael Richard Feldschuh Chief Executive Officer, Director | Mar 10, 2025 | Buy | +3,360 | $7.68 | $25.80K | 210,852 |
| Jonathan Adam Feldschuh Chief Scientific Officer, Director | Dec 6, 2024 | Buy | +32,000 | – | – | 35,908 |
| Michael Richard Feldschuh Chief Executive Officer, Director | Dec 6, 2024 | Buy | +45,000 | – | – | 207,492 |
| Robert J. Michel Chief Financial Officer | Mar 27, 2024 | Buy | +750 | $8.70 | $6.52K | 11,300 |
| Michael Richard Feldschuh Chief Executive Office, Director | Mar 26, 2024 | Buy | +1,000 | $8.13 | $8.13K | 210,631 |
| Michael Richard Feldschuh Chief Executive Officer, Director | Mar 19, 2024 | Buy | +647 | $8.15 | $5.27K | 209,631 |
| Michael Richard Feldschuh Chief Executive Officer, Director | Mar 10, 2024 | Buy | +1,492 | $7.72 | $11.52K | 208,984 |
| Edward Feuer Director | Mar 4, 2024 | Buy | +1,000 | $7.21 | $7.21K | 1,000 |
| Robert J. Michel Chief Financial Officer | Dec 6, 2023 | Buy | +120 | $7.75 | $930 | 10,550 |
| Robert J. Michel Chief Financial Officer | Dec 1, 2023 | Buy | +180 | $7.75 | $1.40K | 10,430 |
| Michael Richard Feldschuh Chief Executive Officer, Director | Dec 1, 2023 | Buy | +800 | $7.80 | $6.24K | 162,492 |
| Robert J. Michel Chief Financial Officer | Nov 24, 2023 | Buy | +500 | $7.94 | $3.97K | 10,250 |
| Michael Richard Feldschuh CHIEF EXECUTIVE OFFICER, Director | Nov 21, 2023 | Award | +84 | $7.65 | $643 | 160,692 |
| Michael Richard Feldschuh CHIEF EXECUTIVE OFFICER, Director | Nov 10, 2023 | Buy | +1,001 | $7.83 | $7.84K | 161,608 |
| Michael Richard Feldschuh CHIEF EXECUTIVE OFFICER, Director | Nov 9, 2023 | Buy | +401 | $7.85 | $3.15K | 160,607 |
| Robert J. Michel Chief Financial Officer | Oct 31, 2023 | Award | +2,000 | – | – | 9,750 |
| Robert J. Michel Chief Financial Officer | Oct 13, 2023 | Buy | +500 | $9.02 | $4.51K | 7,750 |
| of Joseph Feldschuh Estate 10% owner | Sep 18, 2023 | Gift | −25,000 | – | – | 2,549,455 |
| Michael Richard Feldschuh CEO & President | May 24, 2023 | Buy | +2,000 | $9.75 | $19.50K | 160,206 |
| Joy S. Goudie Director | May 24, 2023 | Buy | +300 | $9.75 | $2.93K | 300 |
| Robert J. Michel Chief Financial Officer | Mar 27, 2023 | Buy | +4,750 | – | – | 15,050 |
| Robert J. Michel Chief Financial Officer | Nov 18, 2022 | Buy | +1,000 | $10.00 | $10.00K | 7,250 |
| Caleb DesRosiers Director | Nov 17, 2022 | Buy | +3,157 | $9.50 | $29.99K | 3,157 |
| Robert J. Michel CHIEF FINANCIAL OFFICER | Jun 10, 2021 | Award | +2,000 | – | – | 6,250 |
| Robert J. Michel CHIEF FINANCIAL OFFICER | Apr 19, 2021 | Buy | +1,000 | $10.25 | $10.25K | 4,250 |
| Michael Richard Feldschuh CEO & President | Apr 16, 2021 | Buy | +4,200 | $10.33 | $43.39K | 158,206 |
| of Joseph Feldschuh Estate 10% owner | Jul 22, 2020 | Returned to company | −225,000 | $20.00 | $4.50M | 2,549,455 |
| Edward Feuer Director | Jul 22, 2020 | Returned to company | −1,500 | $19.21 | $28.82K | 0 |
| Robert J. Michel CHIEF FINANCIAL OFFICER | Mar 22, 2019 | Buy | +750 | $13.02 | $9.77K | 3,250 |
| Michael Richard Feldschuh CEO & President | Mar 21, 2019 | Buy | +200 | $12.20 | $2.44K | 154,006 |
| Michael Richard Feldschuh CEO & President | Mar 21, 2019 | Buy | +600 | $12.36 | $7.42K | 153,406 |
| Michael Richard Feldschuh CEO & President | Mar 21, 2019 | Buy | +400 | $12.40 | $4.96K | 153,806 |
| Robert J. Michel CHIEF FINANCIAL OFFICER | Nov 7, 2018 | Buy | +2,500 | $7.42 | $18.55K | 2,500 |
| Soren Thompson VP, Business Development | Jul 31, 2018 | Buy | −1,000 | $5.50 | $5.50K | 1,950 |
| Edward Feuer Director | Jul 13, 2018 | Buy | +1,500 | $6.18 | $9.27K | 1,500 |
| Soren Thompson Vice President | Mar 15, 2018 | Sale | −2,950 | $19.54 | $57.64K | 950 |
| Jonathan Adam Feldschuh Director | Mar 15, 2018 | Sale | −19,194 | $18.63 | $357.58K | 3,908 |
| Michael Richard Feldschuh President, Director | Mar 15, 2018 | Sale | −20,800 | $16.40 | $341.12K | 152,806 |
| Joseph Feldschuh 10% owner | Mar 9, 2018 | Sale | −37,000 | $6.44 | $238.28K | 2,774,455 |
| Michael Richard Feldschuh President & CEO, Director | Oct 17, 2017 | Buy | +2 | $4.66 | $9 | 172,799 |
| Michael Richard Feldschuh President & CEO, Director | Oct 16, 2017 | Buy | +148 | $4.95 | $733 | 172,797 |
| Michael Richard Feldschuh President & CEO, Director | Oct 13, 2017 | Buy | +3 | $4.95 | $15 | 172,649 |
| Michael Richard Feldschuh President & CEO, Director | Oct 12, 2017 | Buy | +49 | $4.95 | $243 | 172,646 |
| Michael Richard Feldschuh President & CEO, Director | Sep 5, 2017 | Buy | +100 | $5.40 | $540 | 173,097 |
| Michael Richard Feldschuh President & CEO, Director | Aug 25, 2017 | Buy | +200 | $5.56 | $1.11K | 172,997 |
| Michael Richard Feldschuh President & CEO, Director | Aug 24, 2017 | Buy | +200 | $5.63 | $1.13K | 172,797 |
| Soren Thompson VP Business Development | Jun 28, 2017 | Buy | +500 | $6.50 | $3.25K | 3,900 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.